Mediana메디아나

Mediana's trailing profits are recovering from a weak 2024, but the share price has fallen over the past one and three months.

Mediana, a Korean maker of hospital patient monitors and defibrillators, reported trailing twelve-month revenue of about ₩71.5B and net income of about ₩9.6B to H1 2026, with a small debt load and a net cash position. The share price closed at ₩8,190 on 23 October 2026, well below its 52-week high of ₩29,600 but far above its 52-week low of ₩4,900. The data does not include any analyst ratings or forecasts.

What stands out

• Revenue fell 27.3% in 2024 to ₩57.0B, then rose 13.9% in 2025 to ₩64.9B; trailing revenue to H1 2026 is ₩71.5B.
• Trailing operating margin is 11.2%, up from 2.3% in 2024 but below the 15.5% peak in 2022.
• Trailing net income of ₩9.6B is higher than trailing operating income of ₩8.0B, so non-operating items or other factors helped; the data does not explain why.
• Cash of about ₩30.9B against liabilities-to-equity of 10.3% and no listed borrowings; trailing free cash flow is about ₩3.7B.
• The shares returned 60.3% over one year but fell 8.1% over one month and 13.7% over three months. Foreign ownership rose from 4.0% to 4.5% over 60 days, while foreign investors were net sellers over the last 20 days.
• Valuation shows a P/E of 15.8, P/B of 1.1 and no dividend. The company's own DCF model gives a base value of ₩7,164, below the current price, with a bear case of ₩5,301 and a bull case of ₩10,338.

What to watch

• The Q3 2026 quarterly report and whether margins hold near the trailing 11.2% level.
• Filing amendments: the Q1 2026 quarterly report was amended in May, and a 2026 half-year report attachment was added in August.
• Continued foreign selling and the gap between the share price and the company's base-case fair value estimate.